Good MorningU.S. markets return from the Labor Day break with investors weighing a surprisingly strong August jobs report. Payroll growth exceeded expectations, unemployment fell to 4.1%, and other labor indicators pointed to continued strength. The data reinforces the idea that the economy remains on solid footing, but it also makes near-term rate cuts increasingly difficult to justify.
That puts Treasury yields and inflation back at the center of the market’s attention. The 10-year yield is testing an important level as investors assess the possibility that interest rates will stay higher for longer, or even rise further if inflation remains stubborn. This week’s CPI report will provide another important signal, with markets looking for evidence that price pressures are easing enough to keep the Federal Reserve on hold.
Earnings will provide another test for stocks. Casey’s General Stores and GameStop report Tuesday evening, followed later in the week by AeroVironment, Optical Cable, and Kroger. Oracle will also be closely watched as investors look for updates on AI-driven demand, data center expansion, and its massive backlog. Featured: BofA: Digital Dollar Coming 2025-2030 (Ad) 
|
Industrials | |
Life has two constants: death and taxes. But if you were to add a third, it might be the U.S. military expanding its annual budget. And now that the war in Iran has drastically depleted the coffers, the U.S. military is once again fiending for firepower. The Pentagon is requesting $1.1 trillion in ... Read the Full Story |
|
From Our Partners | | Trader Chris Pulver says a new SEC document dropping the day-trading limit to $2,000 has created the biggest retail opportunity he has seen in over 30 years.
His strategy targets what he calls Flashpoints - moments when market makers must move billions of dollars on the S-P 500 in a narrow window. Research shows one recent signal would have returned 83.7% in 36 minutes and another 62.8% in 51 minutes.
Lance Ippolito flew to Utah for a full breakdown of the method. | | Tap here to see the complete Flashpoint trading breakdown now |
|
Markets | |
South Korean equities have had a banner year, highlighted by semiconductor giants like SK hynix Inc. (NASDAQ: SKHY), the $1.2-trillion chip giant that has risen more than 10% in the last month alone. The market's performance may lead some investors to wonder whether the opportunity has already come... Read the Full Story |
|
Technology | |
Guidewire Software’s (NYSE: GWRE) post-release stock plunge looks like a knee-jerk reaction that will soon correct.
The plunge was caused by tepid guidance linked to a strategic shift from legacy licensing models to cloud-based subscription models, which provide lower revenue but better margins. T... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Consumer Discretionary | |
Evaluating the electric vehicles and autonomous transport sectors requires looking beyond traditional metrics such as cars produced and delivered. Wall Street now focuses on software recurring revenue and fleet utilization.
The pivot away from consumer retail sales toward commercial robotaxi fleets... Read the Full Story |
|
Energy | |
Despite best efforts of the Trump administration to tease down gas prices amid the ongoing Iran war, the price at the pump has remained stubbornly elevated. While this may hurt investors as they drive their cars, it does present an opportunity. Rather than just buying oil producers, thoughtful inve... Read the Full Story |
|
|
Industrials | |
With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessio... Read the Full Story |
|
Consumer Discretionary | |
At a surface level, Petco Health and Wellness (NASDAQ: WOOF) looks like a company that would be a solid defensive stock for times like these.
Data from the American Pet Products Association forecasts that Americans will spend $165 billion on their pets in 2026, an increase of 4.4% from 2025.
That... Read the Full Story |
|
Technology | |
Investors watching the latest earnings season might have noticed a unique corporate finance maneuver buried beneath standard top-line beats. Hewlett Packard Enterprise (NYSE: HPE) recently executed a strategic equity option, granting millions of shares to a major infrastructure partner.
Retail mar... Read the Full Story |
|
Technology | |
Microsoft Corp. (NASDAQ: MSFT) shares closed at approximately $497 on Sept. 2, which is almost exactly where the stock started 2026. But for investors who owned MSFT at the start of the year, the current price is a relief.
MSFT staged a record-setting post-earnings rally that erased months of loss... Read the Full Story |
|
Consumer Discretionary | |
Lower-income consumers have been pulling back on spending. But the impact on quick-service restaurant stocks hasn’t been the same. In the past, investors may have looked at food quality or brand loyalty to separate winners and losers when sales are down. That doesn’t fit in 2026. The real divide is... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Tuesday, September 08, 2026 at 1:05 AM.
AbbVie Bull Case -
AbbVie Inc. recently announced positive topline results from the Phase 3 CERVINO trial, where its investigational BCMA x CD3 therapy, etentamig, met both primary endpoints for relapsed/refractory multiple myeloma. The therapy produced a 74% objective response rate compared to 45.7% for standard therapies and reduced the risk of disease progression or death by 60%, which could support a regulatory submission and allow the company to compete in the growing BCMA-targeted treatment market.
-
The company completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs to its pipeline. This strategic move strengthens AbbVie Inc.'s growth potential beyond its flagship Humira product and expands its immunology portfolio.
-
AbbVie Inc. reported strong second-quarter earnings, with earnings per share of $3.65 beating analysts' consensus estimates of $3.61 by $0.04. Revenue reached $16.99 billion, exceeding the $16.80 billion estimate, and revenue grew 10.2% on a year-over-year basis, demonstrating robust commercial performance and effective execution.
-
Key growth products Skyrizi and Rinvoq continue to drive significant sales, with reported second-quarter sales growth of 24% and 25% respectively. These products are effectively offsetting the erosion of Humira revenue, providing a stable foundation for the company's financial health and supporting its long-term investment case.
-
AbbVie Inc. maintains a consistent dividend record, having recently declared a quarterly dividend of $1.73 per share, which represents an annualized dividend of $6.92 and a dividend yield of 2.7%. This steady income stream is attractive to investors seeking reliable returns, supported by the company's established financial position.
AbbVie Bear Case -
Humira, the company's flagship drug, continues to face significant headwinds due to biosimilar competition, leading to a decline in revenue. This raises concerns about how quickly newer products can replace the lost cash flow and support future dividend growth, posing a risk to the company's overall financial stability.
-
AbbVie Inc. has a high payout ratio of 195.48%, meaning the company is paying out more in dividends than it is earning in net income. This could strain the company's cash flow and limit its ability to invest in future growth initiatives or weather financial downturns.
-
The Apogee Therapeutics acquisition is expected to dilute AbbVie Inc.'s earnings initially before becoming accretive later in the decade. This short-term earnings dilution could impact the company's financial performance and potentially affect its stock price in the near term.
-
AbbVie Inc. has a high P/E ratio of 72.39, which is significantly above the market average. This suggests that the stock may be overvalued relative to its current earnings, and investors may face limited upside potential if the company's earnings growth does not meet expectations.
-
AbbVie Inc. is currently trading at $256.27, which is below its 52-week high of $267.47. This indicates that the stock has experienced some recent volatility and may be underperforming relative to its peak valuation, potentially signaling market uncertainty or concerns about the company's future prospects.
| | View Today's Stock Pick |
|
